Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in allergic diseases and allergen immunotherapy
NL-OMON45948Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Jan 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial in allergic rhinitis (AR) and allergy, sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Predictive value of candidate biomarkers sIgE/tIgE and IgE-FAB on treatment effect. Started Jan 2020; status: recruiting.
02
Conditions
allergic rhinitis (AR)allergy
Beyond the preview
Go deeper on NL-OMON45948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45948.